Enzymatic properties and clinical associations of serum alpha ‐ galactosidase A in Parkinson's disease
Annals of Clinical and Translational Neurology · 2023
DOI: 10.1002/acn3.51856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Yasuaki Mizutani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. Hauptthemen laut MEDLINE: Fabry Disease, Parkinson Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Recent studies have revealed an association between Parkinson's disease (PD) and Fabry disease, a lysosomal storage disorder; however, the underlying mechanisms remain to be elucidated. This study aimed to investigate the enzymatic properties of serum alpha‐galactosidase A (GLA) and compared them with the clinical parameters of PD.
Methods
The study participants consisted of 66 sporadic PD patients and 52 controls. We measured serum GLA activity and calculated the apparent Michaelis constant ( K m ) and maximal velocity ( V max ) by Lineweaver–Burk plot analysis. Serum GLA protein concentration was measured by enzyme‐linked immunosorbent assay. We examined the potential correlations between serum GLA activity and GLA protein concentration and clinical features and the plasma neurofilament light chain (NfL) level.
Results
Compared to controls, PD patients showed significantly lower serum GLA activity ( P < 0.0001) and apparent V max ( P = 0.0131), but no change in the apparent K m value. Serum GLA protein concentration was lower in the PD group ( P = 0.0168) and was positively associated with GLA activity. Serum GLA activity and GLA protein concentration in the PD group showed a negative correlation with age. Additionally, serum GLA activity was negatively correlated with the motor severity score and the level of plasma NfL, and was positively correlated with the score of frontal assessment battery.
Interpretation
This study highlights that the lower serum GLA activity in PD is the result of a quantitative decrement of GLA protein in the serum and that it may serve as a biomarker of disease severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
- Department of Biomedical Data Science, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Fujita Health University Central Japan International Airport Clinic, Tokoname, Aichi, Japan.
ORCID-Profile: Yasuaki Mizutani, Tatsuro Mutoh
Zitieren
APA
Mizutani, Y., Nawashiro, K., Ohdake, R., Tatebe, H., Shima, S., Ueda, A., Yoshimoto, J., Ito, M., Tokuda, T., Mutoh, T., & Watanabe, H. (2023). Enzymatic properties and clinical associations of serum alpha ‐ galactosidase A in Parkinson's disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51856
Vancouver
Mizutani Y, Nawashiro K, Ohdake R, Tatebe H, Shima S, Ueda A, et al. Enzymatic properties and clinical associations of serum alpha ‐ galactosidase A in Parkinson's disease. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51856
BibTeX
@article{Mizutani2023,
author = {Mizutani, Yasuaki and Nawashiro, Kazuki and Ohdake, Reiko and Tatebe, Harutsugu and Shima, Sayuri and Ueda, Akihiro and Yoshimoto, Junichiro and Ito, Mizuki and Tokuda, Takahiko and Mutoh, Tatsuro and Watanabe, Hirohisa},
title = {Enzymatic properties and clinical associations of serum alpha ‐ galactosidase A in Parkinson's disease},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
doi = {10.1002/acn3.51856}
}
EUVIMED